



ceridemia, and hypertension. Arch Intern Med 1989; 149: 1514–1520.

5. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–1645.

6. Chobufo MD, Gayam V, Soluny J, et al. Prevalence and control rates of hypertension in the USA: 2017–2018. Int J Cardiol Hypertens. 2020; 6: 100044.

7. Widimský J jr, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi. Vnitř Lek. 2018; 64(7–8): 771–796.

8. Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008; 207(6): 928–934.

9. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity Among Adults and Youth: United States, 2015–2016. NCHS Data Brief. 2017; (288): 1–8.

10. Vernooij JW, van der Graaf Y, Visseren FL, Spiering W; SMART study group. The prevalence of obesity-related hypertension and risk for new vascular events in patients with vascular diseases. Obesity (Silver Spring). 2012; 20(10): 2118–2123.

11. Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—a position paper of the The Obesity Society and The American Society of Hypertension. J Clin Hypertens (Greenwich). 2013; 15(1): 14–33.

12. Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020; 9(1): 80–93.

13. Chrysant SG. Pathophysiology and treatment of obesity-related hypertension. J Clin Hypertens (Greenwich). 2019; 21(5): 555–559.

14. Faulkner JL, Belin de Chantemèle EJ. Sex differences in mechanisms of hypertension

associated with obesity. Hypertension. 2018; 71(1): 15–21.

15. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002; 324(3): 127–137.

16. Oliveros E, Somers VK, Sochor O, et al. The concept of normal weight obesity. Prog Cardiovasc, DiS. 2014; 56(4): 426–433.

17. Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017; 122: 1–7.

18. Williams B, Mancia G, Spiering W, et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.

19. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003; 42(5): 878–884.

20. Fried M, Müllerová D, Haluzík M, et al. Společné stanovisko odborných společností k farmakologické léčbě obezity. Gastroent Hepatol 2020; 74(6): 499–512.

21. Briasoulis A, Al Dhaybi O, Bakris GL. SGLT2 Inhibitors and mechanisms of hypertension. Curr Cardiol Rep. 2018; 20(1): 1.

22. Messerli FH, Bangalore S. Diuretic-based regimens for obese patients? Lancet. 2013; 381(9866): 512–513.

23. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006; 60(5): 621–629.

24. Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004; 18(9): 669–675.

25. Fried M, Yumuk V, Oppert JM, et al; European Association for the Study of Obesity; International Federation for the Surgery of Obesity – European Chapter. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts. 2013; 6(5): 449–468.

26. Pareek M, Bhatt DL, Schiavon CA, Schauer PR. Metabolic surgery for hypertension in patients with obesity. Circ Res. 2019; 124(7): 1009–1024.

27. Souček M. Léčba hypertenze u obezity. Kardiolog Rev. 2011; 13(1): 9–13.